Joinn Laboratories (China) Co (SHSE:603127) Cyclically Adjusted Revenue per Share: ¥1.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603127 Joinn Laboratories (China) Co Ltd SHSE:603127
71 GF Score
Price ¥48.14
GF Value ¥17.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Joinn Laboratories (China) Co Cyclically Adjusted Revenue per Share?

Joinn Laboratories (China) Co SHSE:603127 +2.62% 71 Cyclically Adjusted Revenue per Share is ¥1.93 as of Mar. 2026. GuruFocus rates SHSE:603127 with a GF Score™ of 71/100 and a GF Value™ of ¥17.64 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Joinn Laboratories (China) Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.424. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥1.93 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-27), Joinn Laboratories (China) Co's current stock price is ¥48.14. Joinn Laboratories (China) Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥1.93. Joinn Laboratories (China) Co's Cyclically Adjusted PS Ratio of today is 24.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Joinn Laboratories (China) Co was 26.58. The lowest was 11.89. And the median was 18.68.


Joinn Laboratories (China) Co  (SHSE:603127) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Joinn Laboratories (China) Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=48.14/1.93
=24.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Joinn Laboratories (China) Co was 26.58. The lowest was 11.89. And the median was 18.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Joinn Laboratories (China) Co Cyclically Adjusted Revenue per Share Related Terms


Joinn Laboratories (China) Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Joinn Laboratories (China) Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co Cyclically Adjusted Revenue per Share Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.93

Joinn Laboratories (China) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.88 1.89 1.93 1.93

SHSE:603127 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603127
71GF Score
Joinn Laboratories (China) Co Ltd SHSE:603127
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Joinn Laboratories (China) Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Joinn Laboratories (China) Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.424/116.3033*116.3033
=0.424

Current CPI (Mar. 2026) = 116.3033.

Joinn Laboratories (China) Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 100.600 0.000
201609 0.113 102.400 0.128
201612 0.248 102.600 0.281
201703 0.040 103.200 0.045
201706 0.164 103.100 0.185
201709 0.156 104.100 0.174
201712 0.211 104.500 0.235
201803 0.088 105.300 0.097
201806 0.130 104.900 0.144
201809 0.247 106.600 0.269
201812 0.266 106.500 0.290
201903 0.161 107.700 0.174
201906 0.164 107.700 0.177
201909 0.237 109.800 0.251
201912 0.485 111.200 0.507
202003 0.265 112.300 0.274
202006 0.371 110.400 0.391
202009 0.374 111.700 0.389
202012 0.718 111.500 0.749
202103 0.297 112.662 0.307
202106 0.441 111.769 0.459
202109 0.622 112.215 0.645
202112 0.905 113.108 0.931
202203 0.371 114.335 0.377
202206 0.653 114.558 0.663
202209 0.646 115.339 0.651
202212 1.326 115.116 1.340
202303 0.492 115.116 0.497
202306 0.846 114.558 0.859
202309 0.795 115.339 0.802
202312 1.035 114.781 1.049
202403 0.430 115.227 0.434
202406 0.729 114.781 0.739
202409 0.560 115.785 0.563
202412 1.103 114.893 1.117
202503 0.349 115.116 0.353
202506 0.544 114.907 0.551
202509 0.467 115.471 0.470
202512 0.865 115.832 0.869
202603 0.424 116.303 0.424

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥1.93 mean?
Joinn Laboratories (China) Co (SHSE:603127) has a Cyclically Adjusted Revenue per Share of ¥1.93 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Joinn Laboratories (China) Co and its competitors.
Is Joinn Laboratories (China) Co's Cyclically Adjusted Revenue per Share too high?
Joinn Laboratories (China) Co's current Cyclically Adjusted Revenue per Share is ¥1.93. Overall, Joinn Laboratories (China) Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Joinn Laboratories (China) Co's Cyclically Adjusted Revenue per Share of ¥1.93 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Cyclically Adjusted Revenue per Share is ¥1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.64, compared to a current price of ¥48.14 — trading 172.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥1.93. Joinn Laboratories (China) Co's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Cyclically Adjusted Revenue per Share is ¥1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?

Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued. The current stock price of ¥48.14 is trading 172.9% above its estimated GF Value™ of ¥17.64. GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.

Key valuation signals for SHSE:603127:

  • Cyclically Adjusted Revenue per Share: ¥1.93
  • GF Value™: ¥17.64 vs. price of ¥48.14 (172.9% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Joinn Laboratories (China) Co Business Description

Other Exchanges 06127:Hong Kong
Address A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
71GF Score

Get the complete analysis for SHSE:603127

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥48.14
Price
¥17.64
GF Value